Indication
Non-squamous non-small cell lung cancer
17 clinical trials
23 products
7 drugs
Clinical trial
A Randomized, Double-blind, Parallel-controlled Study Comparing the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (SIBP04) and Bevacizumab Injection (Avastin) in Combination With Paclitaxel and Carboplatin Respectively in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer.Status: Completed, Estimated PCD: 2022-12-26
Product
PaclitaxelProduct
SIBP04Product
AvastinProduct
CarboplatinProduct
ABP 215Clinical trial
A Randomized, Double-blind, Phase 3 Bridging Study Evaluating the Safety and Efficacy of ABP 215 Compared With Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerStatus: Withdrawn, Estimated PCD: 2022-11-13
Product
BevacizumabClinical trial
A Phase 2 Study of VLS-101 in Patients With Solid TumorsStatus: Completed, Estimated PCD: 2023-06-12
Product
ZilovertamabClinical trial
Open-label, Phase 2 Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)Status: Not yet recruiting, Estimated PCD: 2024-04-30
Product
TelaglenastatProduct
DocetaxelClinical trial
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)Status: Terminated, Estimated PCD: 2021-11-05
Product
DexamethasoneProduct
TH-4000Product
PemetrexedProduct
PembrolizumabProduct
PlaceboClinical trial
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase InhibitorStatus: Terminated, Estimated PCD: 2017-01-01
Product
PyrotinibProduct
NI-1801Clinical trial
A Phase 1, Open-label, Dose Finding Study of NI-1801, a Bispecific Mesothelin x CD47 Engaging Antibody, in Patients With Mesothelin Expressing Solid CancersStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase II Study of Lenvatinib (E7080/MK-7902) in Combination With Carboplatin Pemetrexed and Pembrolizumab (MK-3475) for Patients With Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR MutationsStatus: Active (not recruiting), Estimated PCD: 2023-10-01
Product
LenvatinibDrug
AN0025Clinical trial
Neo-Bio-ADAURA: A Single Arm, Multi-Centre Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib.Status: Not yet recruiting, Estimated PCD: 2029-01-01
Drug
OsimertinibClinical trial
A Phase II, Multicenter Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR Mutation Positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Chemoradiation Therapy (PLATINUM Trial)Status: Recruiting, Estimated PCD: 2026-03-02
Drug
LazertinibClinical trial
Safety and Efficacy of Anlotinib Hydrochloride Combined With Pemetrexed Plus Cisplatin/Carboplatin (AP) as First Line Treatment for Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung CancerStatus: Completed, Estimated PCD: 2019-11-05
Product
AnlotinibClinical trial
A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCStatus: Recruiting, Estimated PCD: 2024-12-01
Drug
TiragolumabDrug
AtezolizumabClinical trial
Phase II Study of Crizotinib for ROS1 and MET Activated Lung Cancer (CROME)Status: Recruiting, Estimated PCD: 2024-12-01
Product
CrizotinibClinical trial
Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II TrialStatus: Recruiting, Estimated PCD: 2026-03-30
Drug
mFOLFOX6Drug
CisplatinClinical trial
AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line SettingStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
AfatinibClinical trial
Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%: CJLSG1901Status: Active (not recruiting), Estimated PCD: 2023-05-01